Kevin Charles Gorman - May 27, 2025 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role
Director
Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Stock symbol
NBIX
Transactions as of
May 27, 2025
Transactions value $
-$1,157,211
Form type
4
Date filed
5/29/2025, 06:15 PM
Previous filing
May 22, 2025
Next filing
Jun 16, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
GORMAN KEVIN CHARLES Director 6027 EDGEWOOD BEND COURT, SAN DIEGO /s/ Darin Lippoldt, Attorney-in-Fact 2025-05-29 0001201096

Transactions Table

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2025.
F2 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $119.62 to $120.87. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3 514,596 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.